GlassScriptPhysician profile
Sung Wook Sun
NPI 1932125994
$14,079.52
in general payments reported to CMS, 2019-2025
54 companies · $2,671 in 2025
The $2,671 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $1,663 · 2021: $2,289 · 2022: $1,772 · 2023: $1,909 · 2024: $1,761 · 2025: $2,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,286 · Education: $53.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,286.28 |
| Education | $53.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,921.61 | 2019-2025 | Linzess, Creon, Viberzi |
| Novo Nordisk INC | $1,649.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,302.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,035.04 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $880.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $878.12 | 2019-2025 | Farxiga, Lokelma |
| Scilex Pharmaceuticals INC. | $682.19 | 2019-2025 | Ztlido |
| Glaxosmithkline, LLC. | $614.63 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $523.67 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $465.14 | 2019-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $413.51 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $349.48 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $317.24 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.15 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $293.13 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sung Wook Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.